Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Verona Pharma Plc's Business Segments
Verona Pharma Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 103
Regions Reported
-
Verona Pharma Plc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category -
- Product99.8%
- Product and Service, Other0.2%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 103 | 99.8% |
| Product and Service, Other | $ 0 | 0.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Verona Pharma Plc
Verona Pharma Plc is a biopharmaceutical company focused on developing innovative medicines for the treatment of respiratory diseases. The company's lead product candidate, ensifentrine, is a first-in-class bronchodilator and anti-inflammatory agent that has the potential to be used in multiple respiratory conditions, including chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis.
The company was founded in 2005 and is headquartered in London, UK. It has a research and development center in Cardiff, UK, and a clinical development team in the US. Verona Pharma has a global presence and operates in several countries, including the UK, US, Canada, and Australia.
Verona Pharma has a deep and experienced management team, led by CEO Dr. David Zaccardelli, who has extensive experience in drug development and commercialization. The company has a strong scientific team that has published numerous peer-reviewed articles in leading scientific journals.
Verona Pharma has a robust pipeline of product candidates, including nebulized ensifentrine for the treatment of COPD, dry powder ensifentrine for the treatment of asthma, and nebulized ensifentrine for the treatment of cystic fibrosis. The company is also developing a second-generation bronchodilator, RPL554, for the treatment of chronic obstructive pulmonary disease (COPD).
Verona Pharma is focused on bringing its innovative therapies to patients as quickly as possible. The company has a fast-paced, entrepreneurial culture and is committed to attracting and retaining top talent to drive its growth and success. Verona Pharma has a strong commitment to patient-centricity, focusing on delivering meaningful benefits to patients and their families in respiratory disease treatment.
The company was founded in 2005 and is headquartered in London, UK. It has a research and development center in Cardiff, UK, and a clinical development team in the US. Verona Pharma has a global presence and operates in several countries, including the UK, US, Canada, and Australia.
Verona Pharma has a deep and experienced management team, led by CEO Dr. David Zaccardelli, who has extensive experience in drug development and commercialization. The company has a strong scientific team that has published numerous peer-reviewed articles in leading scientific journals.
Verona Pharma has a robust pipeline of product candidates, including nebulized ensifentrine for the treatment of COPD, dry powder ensifentrine for the treatment of asthma, and nebulized ensifentrine for the treatment of cystic fibrosis. The company is also developing a second-generation bronchodilator, RPL554, for the treatment of chronic obstructive pulmonary disease (COPD).
Verona Pharma is focused on bringing its innovative therapies to patients as quickly as possible. The company has a fast-paced, entrepreneurial culture and is committed to attracting and retaining top talent to drive its growth and success. Verona Pharma has a strong commitment to patient-centricity, focusing on delivering meaningful benefits to patients and their families in respiratory disease treatment.
Verona Pharma Plc is a biopharmaceutical company deeply committed to developing and commercializing innovative therapies specifically geared towards managing respiratory diseases. The company operates through several defined segments, integrates comprehensive product lines, and offers a variety of services aimed at enhancing patient care within the respiratory therapeutic landscape.
Segments:
1. Respiratory Diseases:
Verona Pharma Plc places a significant emphasis on treating respiratory diseases. This segment includes the development of therapies for prevalent conditions such as:
- Chronic Obstructive Pulmonary Disease (COPD): Recognized as a leading cause of morbidity and mortality worldwide, COPD encompasses progressive lung diseases that result in airway blockage and breathing-related issues. Verona Pharma’s focus within this domain aims at improving the quality of life for these patients through advanced therapeutic options.
- Asthma: This segment addresses obstructive lung diseases characterized by chronic inflammation and airway hyperreactivity. Verona’s efforts are directed at patients with moderate to severe forms of asthma who may require alternative therapeutic approaches beyond standard inhaled corticosteroids.
- Cystic Fibrosis: This hereditary condition leads to severe damage to the lungs and digestive system due to the production of thick, sticky mucus. Verona Pharma aims to provide specialized therapies that can help mitigate the challenges faced by these patients.
- Bronchiectasis: This chronic lung condition results from the abnormal widening of the bronchi, leading to excessive mucus production and recurrent respiratory infections. Verona Pharma’s strategic initiatives focus on addressing this under-recognized disease to improve patient care.
2. Specialty Pharmaceuticals:
Within this segment, Verona Pharma focuses on niche pharmaceutical products tailored to the unique needs of patients with complex respiratory conditions. These specialty products are often characterized by higher complexity in terms of administration, side effects management, and the need for specialized knowledge by healthcare providers.
Products:
1. RPL554:
RPL554 is Verona Pharma’s flagship product, described as a first-in-class, inhaled dual inhibitor targeting enzymes phosphodiesterase 3 and
- Indications: The primary targets for RPL554 are COPD and cystic fibrosis. The innovative pharmacological action of this compound is thought to provide significant therapeutic benefits by reducing airway inflammation and promoting bronchodilation, thereby improving lung function and respiratory symptoms.
2. Ensifentrine:
Ensifentrine is another key product in Verona Pharma’s pipeline, also categorized as a first-in-class, inhaled dual inhibitor. It works on phosphodiesterase 3 and 4 enzymes and alpha-7 nicotinic acetylcholine receptors.
- Indications: Ensifentrine is being investigated for the management of COPD and asthma. The therapeutic profile aims to combine anti-inflammatory and bronchodilator effects, which may provide comprehensive management for patients with these chronic conditions.
Services:
1. Clinical Trials:
Verona Pharma boasts a robust clinical trials framework aimed at developing its candidate therapies further. The clinical trial program is meticulously designed to assess the safety and efficacy of its products in well-structured phases. This not only reflects the companys commitment to scientific rigor but also paves the way for potential regulatory approvals and commercial launch.
2. Patient Support:
Recognizing the challenges faced by patients with respiratory diseases, Verona Pharma offers extensive patient support services. These programs include:
- Educational Resources: Comprehensive materials are provided to help patients understand their conditions and the importance of adherence to therapy.
- Patient Assistance Programs: These are designed to minimize the financial burden associated with medication costs, thereby enhancing access to essential therapies.
- Support Groups: Facilitation of community connections among patients allows for shared experiences and support, fostering a sense of belonging and understanding.
3. Medical Education:
Verona Pharma is dedicated to enhancing the knowledge of healthcare professionals regarding respiratory diseases and their treatment options. The medical education services encompass:
- Training Programs: Ongoing educational initiatives are aimed at equipping healthcare providers with the latest insights on innovative therapies, patient management strategies, and clinical best practices in the field of respiratory care.
- Professional Workshops: These interactive sessions provide hands-on learning experiences focused on the complexities of respiratory conditions and emerging treatment modalities.
Conclusion:
Through its focused segments, innovative product offerings, and comprehensive services, Verona Pharma Plc positions itself as a leader in advancing therapies for respiratory diseases. Their commitment to research and patient care underscores their mission to enhance the lives of individuals impacted by these chronic conditions, thereby ensuring that patients receive the most effective treatments available.
Segments:
1. Respiratory Diseases:
Verona Pharma Plc places a significant emphasis on treating respiratory diseases. This segment includes the development of therapies for prevalent conditions such as:
- Chronic Obstructive Pulmonary Disease (COPD): Recognized as a leading cause of morbidity and mortality worldwide, COPD encompasses progressive lung diseases that result in airway blockage and breathing-related issues. Verona Pharma’s focus within this domain aims at improving the quality of life for these patients through advanced therapeutic options.
- Asthma: This segment addresses obstructive lung diseases characterized by chronic inflammation and airway hyperreactivity. Verona’s efforts are directed at patients with moderate to severe forms of asthma who may require alternative therapeutic approaches beyond standard inhaled corticosteroids.
- Cystic Fibrosis: This hereditary condition leads to severe damage to the lungs and digestive system due to the production of thick, sticky mucus. Verona Pharma aims to provide specialized therapies that can help mitigate the challenges faced by these patients.
- Bronchiectasis: This chronic lung condition results from the abnormal widening of the bronchi, leading to excessive mucus production and recurrent respiratory infections. Verona Pharma’s strategic initiatives focus on addressing this under-recognized disease to improve patient care.
2. Specialty Pharmaceuticals:
Within this segment, Verona Pharma focuses on niche pharmaceutical products tailored to the unique needs of patients with complex respiratory conditions. These specialty products are often characterized by higher complexity in terms of administration, side effects management, and the need for specialized knowledge by healthcare providers.
Products:
1. RPL554:
RPL554 is Verona Pharma’s flagship product, described as a first-in-class, inhaled dual inhibitor targeting enzymes phosphodiesterase 3 and
- Indications: The primary targets for RPL554 are COPD and cystic fibrosis. The innovative pharmacological action of this compound is thought to provide significant therapeutic benefits by reducing airway inflammation and promoting bronchodilation, thereby improving lung function and respiratory symptoms.
2. Ensifentrine:
Ensifentrine is another key product in Verona Pharma’s pipeline, also categorized as a first-in-class, inhaled dual inhibitor. It works on phosphodiesterase 3 and 4 enzymes and alpha-7 nicotinic acetylcholine receptors.
- Indications: Ensifentrine is being investigated for the management of COPD and asthma. The therapeutic profile aims to combine anti-inflammatory and bronchodilator effects, which may provide comprehensive management for patients with these chronic conditions.
Services:
1. Clinical Trials:
Verona Pharma boasts a robust clinical trials framework aimed at developing its candidate therapies further. The clinical trial program is meticulously designed to assess the safety and efficacy of its products in well-structured phases. This not only reflects the companys commitment to scientific rigor but also paves the way for potential regulatory approvals and commercial launch.
2. Patient Support:
Recognizing the challenges faced by patients with respiratory diseases, Verona Pharma offers extensive patient support services. These programs include:
- Educational Resources: Comprehensive materials are provided to help patients understand their conditions and the importance of adherence to therapy.
- Patient Assistance Programs: These are designed to minimize the financial burden associated with medication costs, thereby enhancing access to essential therapies.
- Support Groups: Facilitation of community connections among patients allows for shared experiences and support, fostering a sense of belonging and understanding.
3. Medical Education:
Verona Pharma is dedicated to enhancing the knowledge of healthcare professionals regarding respiratory diseases and their treatment options. The medical education services encompass:
- Training Programs: Ongoing educational initiatives are aimed at equipping healthcare providers with the latest insights on innovative therapies, patient management strategies, and clinical best practices in the field of respiratory care.
- Professional Workshops: These interactive sessions provide hands-on learning experiences focused on the complexities of respiratory conditions and emerging treatment modalities.
Conclusion:
Through its focused segments, innovative product offerings, and comprehensive services, Verona Pharma Plc positions itself as a leader in advancing therapies for respiratory diseases. Their commitment to research and patient care underscores their mission to enhance the lives of individuals impacted by these chronic conditions, thereby ensuring that patients receive the most effective treatments available.